SARS-CoV-2 EPIDEMICS AND DIABETES

Abstract

An editorial related to the recent SARS-CoV-2 ep- idemics in a diabetes/metabolism journal might seem strange. However, the implications for diabetes sub- jects, usually defined as a vulnerable population in this respect, make worth this endeavor. Moreover, the SARS-CoV-2 epidemic comes on top of the long-time recognized “diabetes epidemic” that does not show signs of relenting. Thus, the latest International Dia- betes Federation (IDF) data show that 463 million peo- ple are affected worldwide, an increase of 38 million compared to 2017. In addition, total healthcare costs associated with diabetes are estimated to around 760 billion USD